ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2501

Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Abstract Number: 2502

Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease
Abstract Number: 2503

Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben
Abstract Number: 2504

Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Abstract Number: 2505

C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Abstract Number: 2506

THP1-derived Macrophage Polarization in Takayasu Arteritis – Impact of Disease Status and Therapy
Abstract Number: 2507

IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil
Abstract Number: 2508

The Impact of Lipid Profile Parameters on the Incidence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients: A Single-arm Meta-Analysis
Abstract Number: 2509

Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Abstract Number: 2510

The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Abstract Number: 2511

Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis
Abstract Number: 2512

French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy
Abstract Number: 2513

Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data
Abstract Number: 2514

The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments
Abstract Number: 2515

Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].